home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630663.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
36 lines
Document 0663
DOCN M9630663
TI Novel non-nucleoside inhibitors of human immunodeficiency virus type 1
reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of
nevirapine.
DT 9603
AU Kelly TA; Proudfoot JR; McNeil DW; Patel UR; David E; Hargrave KD; Grob
PM; Cardozo M; Agarwal A; Adams J; Research and Development Center,
Boehringer Ingelheim; Pharmaceuticals Inc., Ridgefield, Connecticut
06877, USA.
SO J Med Chem. 1995 Nov 24;38(24):4839-47. Unique Identifier : AIDSLINE
MED/96083812
AB Molecular modeling analysis of the recently published X-ray crystal
structure of nevirapine bound to wild type human immunodeficiency virus
type 1 reverse transcriptase (WT-RT) indicated the presence of a
lipophilic cavity proximal to the 4-position of the inhibitor. A series
of 4-substituted derivatives of nevirapine were thus synthesized to
assess structure-activity relationships (SARs) and to see if increased
binding to this region might translate into greater activity against
mutant RTs. The results show that compounds with an appropriately spaced
aryl ring appended to the 4-position of the dipyridodiazepinone ring
system show good activity against WT-RT. Furthermore certain derivatives
appear to inhibit the Y181C mutant RT. Attempts to combine these results
with the recent discovery that 2-substituents enhance activity against
the Y181C mutant led to a few compounds with moderate activity against
both enzymes. The SAR of these two positions, however, could not be
combined in a simple fashion.
DE Comparative Study Human HIV-1 Models, Molecular Molecular
Conformation Pyridines/*CHEMISTRY/CHEMICAL SYNTHESIS Reverse
Transcriptase Inhibitors/*CHEMISTRY/CHEMICAL SYNTHESIS
Structure-Activity Relationship JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).